Docoh
Loading...

BIIB Biogen

At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.

Company profile

Ticker
BIIB
Exchange
Website
CEO
George Scangos
Employees
Incorporated
Location
Fiscal year end
Former names
BIOGEN IDEC INC, BIOGEN IDEC INC., IDEC PHARMACEUTICALS CORP / CA, IDEC PHARMACEUTICALS CORP / DE
SEC CIK
IRS number
330112644

BIIB stock data

(
)

Calendar

22 Jul 21
4 Aug 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Biogen earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B
Cash burn (monthly) (positive/no burn) 53.58M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) n/a 62.68M n/a n/a n/a n/a
Cash remaining n/a 1.68B n/a n/a n/a n/a
Runway (months of cash) n/a 31.3 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Jul 21 Kramer Robin Common Stock Payment of exercise Dispose F No No 348.92 74 25.82K 871.348
1 Jul 21 Kramer Robin Common Stock Option exercise Aquire M No No 348.92 251 87.58K 945.348
1 Jul 21 Kramer Robin RSU Common Stock Option exercise Dispose M No No 0 251 0 504
1 Jul 21 Jones William D Common Stock Grant Aquire A No No 0 775 0 775
1 Jul 21 Hawkins William A Common Stock Grant Aquire A No No 0 775 0 2,820
1 Jul 21 Mantas Jesus B Common Stock Grant Aquire A No No 0 775 0 3,718

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

83.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1043 1030 +1.3%
Opened positions 131 174 -24.7%
Closed positions 118 153 -22.9%
Increased positions 339 272 +24.6%
Reduced positions 387 414 -6.5%
13F shares
Current Prev Q Change
Total value 34.91B 31.47B +10.9%
Total shares 125.06M 128.53M -2.7%
Total puts 4.56M 5.83M -21.9%
Total calls 4.62M 5.76M -19.8%
Total put/call ratio 1.0 1.0 -2.5%
Largest owners
Shares Value Change
Primecap Management 16.76M $4.69B +5.9%
BLK Blackrock 13.5M $3.78B +0.6%
Vanguard 11.85M $3.32B -0.4%
STT State Street 6.67M $1.87B -4.6%
Wellington Management 5.9M $1.65B +2.1%
Clearbridge Advisors 3.97M $1.11B +10.3%
JPM JPMorgan Chase & Co. 3.89M $1.09B +33.5%
Geode Capital Management 2.8M $780.82M +1.3%
BK Bank Of New York Mellon 2.18M $609.04M +1.4%
NTRS Northern Trust 2.12M $593.21M -3.7%
Largest transactions
Shares Bought/sold Change
Norges Bank 0 -1.9M EXIT
Renaissance Technologies 1.94M -1.1M -36.2%
JPM JPMorgan Chase & Co. 3.89M +974.88K +33.5%
Primecap Management 16.76M +936.19K +5.9%
Southeastern Asset Management 603.89K +603.89K NEW
Orbimed Advisors 82K -447.4K -84.5%
Susquehanna International 260.64K -417.25K -61.6%
Clearbridge Advisors 3.97M +370.37K +10.3%
AustralianSuper Pty 507.78K +368.3K +264.1%
Marshall Wace 162.56K -357.3K -68.7%

Financial report summary

?
Risks
  • We are substantially dependent on revenue from our products.
  • Our long-term success depends upon the successful development of new products and additional indications for our existing products.
  • If we fail to compete effectively, our business and market position would suffer.
  • We depend on relationships with collaborators, joint venture partners and other third parties for revenue, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.
  • Our results of operations may be adversely affected by current and potential future healthcare reforms.
  • Our success in commercializing biosimilars is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If we are unsuccessful in such activities, our business may be adversely affected.
  • If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed.
  • Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.
  • Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied.
  • Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.
  • The illegal distribution and sale by third parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.
  • The increasing use of social media platforms presents new risks and challenges.
  • A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.
  • Management and key personnel changes may disrupt our operations, and we may have difficulty retaining key personnel or attracting and retaining qualified replacements on a timely basis for management and other key personnel who may leave the Company.
  • If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.
  • Our sales and operations are subject to the risks of doing business internationally.
  • We are building a large-scale biologics manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.
  • Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenue.
  • Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.
  • The ongoing COVID-19 pandemic may, directly or indirectly, adversely affect our business, results of operations and financial condition.
  • Our operating results are subject to significant fluctuations.
  • Our investments in properties may not be fully realized.
  • Our investment portfolio is subject to market, interest and credit risk that may reduce its value.
  • There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.
  • We may not be able to access the capital and credit markets on terms that are favorable to us.
  • Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business.
  • Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.
  • Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.
Management Discussion
  • Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer’s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.
  • Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS (RMS); and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 18, Collaborative and Other Relationships, to our
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Good
New words: ADUHELM, autoimmune, Breakthrough, Bruton, cease, cinpanemab, cognitive, customary, diagnostic, endpoint, field, GMP, gradual, Hong, House, hybrid, InnoCare, Justice, Kong, Macau, mild, nonrecurring, opicinumab, orelabrutinib, penalty, prespecified, reassessed, reassessing, STAR, SWISSMEDIC, tyrosine, upheld, uptake, verify
Removed: amendment, bring, bringing, culture, degenerative, depending, flat, half, inherited, maintenance, networking, online, palsy, rare, retinal, supraneuclear, unfavorable, unpredictability, voted

Patents

APP
Utility
Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
22 Jul 21
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s).
GRANT
Utility
Controlled release pharmaceutical compositions comprising a fumaric acid ester
6 Jul 21
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s).
APP
Utility
Methods of Intravenous Administration of Glyburide
27 May 21
The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 μg/hr and about 300 μg/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.
APP
Utility
Aav Compositions, Methods of Making and Methods of Use
20 May 21
Disclosed are methods for the purification of a recombinant AAV (rAAV) particle from a mammalian host cell culture.
APP
Utility
Compositions and Methods for the Treatment of Stargardt Disease
20 May 21
The present disclosure provides an adeno-associated viral (AAV) vector system for expressing a human ABCA4 protein in a target cell, the AAV vector system comprising a first AAV vector comprising a first nucleic acid sequence and a second AAV vector comprising a second nucleic acid sequence; wherein the first nucleic acid sequence comprises a 5′ end portion of an ABCA4 coding sequence (CDS) and the second nucleic acid sequence comprises a 3′ end portion of an ABCA4 CDS, and the 5′ end portion and the 3′ end portion together encompass the entire ABCA4 CDS; wherein the first nucleic acid sequence comprises a sequence of contiguous nucleotides corresponding to nucleotides 105 to 3597 of SEQ ID NO: 1; wherein the second nucleic acid sequence comprises a sequence of contiguous nucleotides corresponding to nucleotides 3806 to 6926 of SEQ ID NO: 1; wherein the first nucleic acid sequence and the second nucleic acid sequence each comprise a region of sequence overlap with the other; and wherein the region of sequence overlap comprises at least about 20 contiguous nucleotides of a nucleic acid sequence corresponding to nucleotides 3598 to 3805 of SEQ ID NO: 1.